Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2025 4
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Bohula EA, et al. Among authors: paiva da silva lima g. N Engl J Med. 2026 Jan 8;394(2):117-127. doi: 10.1056/NEJMoa2514428. Epub 2025 Nov 8. N Engl J Med. 2026. PMID: 41211925 Clinical Trial.
BACKGROUND: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery disease. ...CONCLUSIONS: …
BACKGROUND: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascul …
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Marston NA, et al. Among authors: da silva lima gp. JAMA. 2026 Apr 28;335(16):1400-1407. doi: 10.1001/jama.2026.3277. JAMA. 2026. PMID: 41903215 Clinical Trial.
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. ...CONCLUS …
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type …
Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.
Monguillon V, Kelly PJ, O'Donoghue ML, Park JG, Bohula EA, Saver JL, Atar D, Keech AC, Sever PS, Wang H, Paiva da Silva Lima G, Sabatine MS, Giugliano RP. Monguillon V, et al. Among authors: paiva da silva lima g. Circulation. 2026 Jan 13;153(2):86-93. doi: 10.1161/CIRCULATIONAHA.125.077549. Epub 2025 Nov 3. Circulation. 2026. PMID: 41178569 Free article. Clinical Trial.
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear. METHODS: We analyze …
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular event …
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.
Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, Gouni-Berthold I, Paiva da Silva Lima G, Handelsman Y, Lewis BS, Ohman EM, Wang H, López JAG, Monsalvo ML, Sabatine MS, Leiter LA. Kang YM, et al. Among authors: paiva da silva lima g. Diabetes Care. 2025 Sep 1;48(9):1512-1516. doi: 10.2337/dc25-0942. Diabetes Care. 2025. PMID: 40544474 Clinical Trial.
RESEARCH DESIGN AND METHODS: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) randomized participants with atherosclerotic cardiovascular disease (ASCVD) on statins to evolocumab or placebo (median follow-up 2.2 …
RESEARCH DESIGN AND METHODS: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) …
Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.
Leiter LA, Giugliano RP, Marston NA, De Ferrari G, Nicolau JC, Bhatia AK, Cyrille M, Park JG, Kuder JF, Murphy SA, Liu L, Walsh E, Wang H, Džupina A, Ferreira J, Gouni-Berthold I, Jensen HK, Kuusisto J, Pella D, Sattar N, Tsioufis KP, Vinereanu D, Paiva da Silva Lima G, Sabatine MS, Bohula EA. Leiter LA, et al. Among authors: paiva da silva lima g. Diabetes Care. 2026 Jun 7:dc260847. doi: 10.2337/dc26-0847. Online ahead of print. Diabetes Care. 2026. PMID: 42251764
OBJECTIVE: This prespecified analysis of Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV) evaluated the efficacy of the PCSK9 inhibitor evolocumab for preventing first cardiovascular events in p …
OBJECTIVE: This prespecified analysis of Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarc …
Characterisation of a clinical trial-like population of high cardiovascular risk patients prior to myocardial infarction or stroke in the real world: design and protocol for a multidatabase retrospective cohort study.
Ochs A, Chan Q, Dhalwani NN, Duxbury M, Shannon E, O'Kelly J, Paiva da Silva Lima G, Avcil S, Chan AY, Chui CS, Lai EC, Cars T, Shin JJ, Heintjes EM, Wong IC. Ochs A, et al. Among authors: paiva da silva lima g. BMJ Open. 2025 Jul 30;15(7):e092702. doi: 10.1136/bmjopen-2024-092702. BMJ Open. 2025. PMID: 40738626 Free PMC article.
INTRODUCTION: Cardiovascular (CV) disease is the leading cause of morbidity and mortality globally. Low-density lipoprotein cholesterol (LDL-C) is an important modifiable risk factor of major adverse cardiovascular events. ...The benefits of evolocumab, a proprotein …
INTRODUCTION: Cardiovascular (CV) disease is the leading cause of morbidity and mortality globally. Low-density lipoprotein cholester …
Early versus delayed evolocumab treatment and complex coronary artery revascularization.
Haller PM, Gaba P, Thomas C, Fagundes A, Oyama K, Furtado RHM, Zelniker TA, Kuder J, Murphy S, Verma S, Wang H, da Silva Lima GP, Ohman EM, Braunwald E, Giugliano RP, O'Donoghue ML, Sabatine MS, Bergmark BA. Haller PM, et al. Among authors: da silva lima gp. Eur J Prev Cardiol. 2026 Jun 16:zwag304. doi: 10.1093/eurjpc/zwag304. Online ahead of print. Eur J Prev Cardiol. 2026. PMID: 42301217 Free article.
BACKGROUND: In FOURIER, the PCSK9 inhibitor evolocumab (Evo) significantly reduced the rate of major adverse cardiovascular events and coronary revascularization. AIMS: To investigate the effect of evolocumab on the incidence of complex coronary revascularization during lo …
BACKGROUND: In FOURIER, the PCSK9 inhibitor evolocumab (Evo) significantly reduced the rate of major adverse cardiovascular events an …